|
Post by marriott on Aug 1, 2021 16:54:26 GMT
In an article in National Review published today , Caroline Downey reported “ With vaccination rates plateauing in certain regions of the country as a new COVID wave triggered by the highly infectious Delta variant spreads, the Food and Drug Administration (FDA) has signaled it will expedite the process to fully approve the COVID vaccine. A top agency official said Friday that the Pfizer-BioNTech shot will be under accelerated review to earn the designation. “
About a month ago in article in The Lancet , it was reported that “two doses of the vaccines from Pfizer and BioNTech and from AstraZeneca still provide strong protection, although not as strong as the protection provided against the alpha variant. Two weeks after the second dose, the Pfizer/BioNTech vaccine was found to provide 79% protection against infection from the delta variant, compared to 92% against the alpha variant. With AstraZeneca's vaccine, there was 60% protection against delta compared with 73% for alpha. Because this was an observational study, more research is needed to confirm the findings, the research team said.
If results from any credible source find that Novavax’s efficacy against the Delta variant exceed 80 per cent , momentum towards moving 2373 towards “ approval “ in some form will be strong , fast and a perception changer.
|
|